Brigatinib/Brigatinib generally has no progression period for several years

Brigatinib is a targeted drug used to treat non-small cell lung cancer (NSCLC), specifically those with ALK (anaplastic lymphoma kinase) gene rearrangements. Based on current clinical trial data and research results, brigatinib can prolong progression-free survival (PFS) in patients. Each patient's condition and treatment response may be different. Therefore, the progression-free period of brigatinib may vary in different patients.

Progression-Free Survival (PFS) is one of the important indicators for evaluating the effect of cancer treatment. It refers to the time from the beginning of treatment to the progression or death of the patient (regardless of the cause). It is generally affected by a variety of factors, including but not limited to the patient's specific illness, physical condition, tumor stage, gene mutation, previous treatment history, and side effects and tolerance during treatment.

One study included 222 patients whose disease progressed despite prior treatment with crizotinib. Among patients who received brigatinib at 90 mg daily and increased to 180 mg after 7 days, approximately 56% showed a complete or partial response to the drug, with responses maintained for an average of approximately 14 months. Another study involved 275 patients who had not previously received ALK inhibitors. In the study, patients who received brigatinib took an average of 24 months for their disease to worsen, compared with 11 months for those who received crizotinib.

The efficacy and tolerability of brigatinib may also be affected by other factors, such as the patient's genetic mutation and whether he has received other ALK inhibitors before treatment. Therefore, when using brigatinib as a treatment option, doctors will develop an individualized treatment plan based on the patient's specific conditions.